MedTrace Logo

PET/MRI in Endometrial Cancer

NCT05390021 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-04-02

No results posted yet for this study

Summary

This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography \[CT\], or PET/CT) for high-risk endometrial cancer.

The name of the intervention involved in this study is:

Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)

Conditions

  • Cytoreductive Surgery
  • Grade 3 Endometrial Endometrioid Adenocarcinoma
  • High Grade Serous Carcinoma
  • Endometrial Undifferentiated Carcinoma
  • Endometrial Mixed Cell Adenocarcinoma

Interventions

COMBINATION_PRODUCT

PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent

The research study procedures include a screening for eligibility and a single study visit. PET/MRI in one study visit of approximately four hours.

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Onofrio Catalono, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2025-02-01
Completion
2026-02-01
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05390021 on ClinicalTrials.gov